Navigation Links
Dartmouth researchers develop new approach to chronic lymphocytic leukemia treatment

March 14, 2014 Lebanon, NH - Dartmouth researchers have developed a novel and unique approach to treating Chronic Lymphocytic Leukemia (CLL), a form of blood cancer that often requires repeated chemotherapy treatments to which it grows resistant. The researchers, led by Alexey V. Danilov, MD, PhD, assistant professor at the Geisel School of Medicine at Dartmouth and Hematologist-Oncologist at the Norris Cotton Cancer Center, modeled the lymph node microenvironment where CLL cells are found in the laboratory. They were able to disrupt the activity of a pathway (NF-kappaB) that ensures the survival and resistance of the CLL cells in such microenvironments. The study findings were published in the March 15, 2014 issue of Clinical Cancer Research.

"In this in vitro microenvironment, we used MLN4924 to disrupt the activity of the NF-kappaB pathway by targeting Nedd8, which controls activation of NF-kappaB," said Danilov. "This decreased the survival of CLL cells and re-sensitized them to conventional chemotherapy as well as novel agents. Because the CLL cells used were obtained from patients with this disorder, these findings are immediately relevant to the clinic."

Danilov says that unlike other novel therapies that have shown promise in the treatment of CLL, this approach is unique because it does not directly target proteins within the B-cell receptor pathway. He also notes that other research models that mimic the natural lymph node microenvironment have typically induced prolonged survival of CLL cells and made them resistant to in vitro chemotherapy. This research used novel model systems which reversed the pro-survival effects of the microenvironment.

The researchers are now working to understand the intricate mechanisms of how MLN4924 decreased the survival of CLL cells. Once they understand the mechanisms involved, new therapeutic approaches and drug combinations can be developed for use in animal studies of CLL, and may ultimately lead to a clinical trial with human patients.


Contact: Robin Dutcher
The Geisel School of Medicine at Dartmouth

Related medicine news :

1. Dartmouth researchers investigate the cognitive effects of athlete head impacts
2. Mayo Clinic, Dartmouth-Hitchcock announce collaboration
3. Dartmouth medical research closes in on new tuberculosis vaccine
4. Leap in leukemia treatment reported by Dartmouth researchers
5. Dartmouth researchers test safety of Nivolumab in kidney cancer
6. Dartmouth researchers develop molecular switch that changes liquid crystal colors
7. Dartmouth researchers receive $5.9 million grant from NIH for lung research
8. Clemson, Dartmouth use $1.5M grant to develop mobile health technology
9. Dartmouth researcher finds novel genetic patterns that make us rethink biology and individuality
10. Dartmouth study provides first global evidence that foreign aid boosts public opinion
11. NIH awards $20 million over 5 years to train next generation of global health researchers
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... ... kind product that targets the unique health needs of new moms. Postnatal ... Pregnancy Association ( ), utilizes Nordic Naturals’ exclusive, new, ultra-concentrated omega-3 ...
(Date:10/13/2015)... ... 2015 , ... California Southern University has named Dr. Judith ... Doctor of Nursing Practice from the renowned Johns Hopkins University—comes to CalSouthern with ... McLeod’s long and successful nursing practice included a variety of patient care, education ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... Bill Saye as the newest professional to introduce the latest development, ThermiVa® temperature ... recognized as a leading professional in Obstetrics and Gynecology and a pioneer in ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... home furnishings and décor, today announced it closed on a $20.5 million funding ... will be used to support the Company’s continued rapid growth and expansion, broaden ...
(Date:10/13/2015)... ... 2015 , ... The Bill Howe Family of Companies is an award winning ... flood remediation services. Family-owned and operated for 35 years, they have maintained value, ethics ... plumber two years in a row from the Union Tribune Reader’s Poll, a Healthiest ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... N.C. , Oct. 13, 2015  Yesterday Congresswoman ... Influenza Vaccines Holly Springs manufacturing site located in ... 2014, the facility has produced Flucelvax ® (Influenza ... the potential for faster start-up and is not reliant ... CSL Limited acquired the influenza vaccines business of Novartis ...
(Date:10/12/2015)... 12, 2015 Given the intricacy of ... challenging to deliver an ophthalmic drug effectively to a specific ... successful ocular drug delivery. These include dilution of a drug ... of conjunctiva and drug permeation issues with respect to the ... topical eye drops, is lost due to the aforementioned barriers. ...
(Date:10/12/2015)... CRANBURY, N.J. , Oct. 12, 2015 /PRNewswire/ ... that a securities fraud class action complaint was ... of New Jersey.  The complaint alleges that officers and ... Securities Exchange Act of 1934 between September 15, 2015 ... misleading statements about Amicus Therapeutics, business prospects.  Amicus is ...
Breaking Medicine Technology: